KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Short term Debt (2018 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Short term Debt data on record, last reported at $10.0 million in Q4 2025.

  • For Q4 2025, Short term Debt rose 38338.46% year-over-year to $10.0 million; the TTM value through Dec 2025 reached $10.0 million, up 38338.46%, while the annual FY2025 figure was $10.0 million, 38338.46% up from the prior year.
  • Short term Debt reached $10.0 million in Q4 2025 per AQST's latest filing, up from $6.3 million in the prior quarter.
  • Across five years, Short term Debt topped out at $18.7 million in Q4 2022 and bottomed at $22000.0 in Q4 2023.
  • Average Short term Debt over 5 years is $6.4 million, with a median of $4.9 million recorded in 2021.
  • Peak YoY movement for Short term Debt: plummeted 99.88% in 2023, then skyrocketed 38338.46% in 2025.
  • A 5-year view of Short term Debt shows it stood at $2.0 million in 2021, then skyrocketed by 823.46% to $18.7 million in 2022, then tumbled by 99.88% to $22000.0 in 2023, then increased by 18.18% to $26000.0 in 2024, then surged by 38338.46% to $10.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short term Debt were $10.0 million in Q4 2025, $6.3 million in Q3 2025, and $3.2 million in Q2 2025.